Business Context and Reporting Period
This Form 8-K Current Report was filed by Glaukos Corporation on July 19, 2021. The filing addresses a Regulation FD Disclosure regarding the Centers for Medicare & Medicaid Services (CMS) proposed payment rates for Calendar Year 2022. The report focuses on reimbursement changes for Glaukos' trabecular micro-bypass technologies (iStent, iStent inject, iStent inject W) and the iStent infinite product when used in combination with cataract surgery or as standalone procedures.
Key Financial Metrics and Payment Rates
The filing does not provide consolidated revenue, profit, cash flow, or debt metrics. Instead, it details specific proposed facility fee payment rates for 2022 compared to current rates under Category III codes:
- ASC Setting (CPT 669X2/669X1): Proposed rate of $2,516 versus current rate of $3,353.
- HOPD Setting (CPT 669X2/669X1): Proposed rate of $4,019 versus current rate of $3,918.
- Standalone Insertion (CPT 01X2T): Proposed ASC rate of $2,516 and HOPD rate of $2,131.
Material Changes Versus Prior Period
The primary material change involves a shift from Category III CPT code 0191T to new Category I codes (669X1 and 669X2) for combined cataract and aqueous drainage device procedures. This transition results in:
- A significant decrease in proposed reimbursement for the Ambulatory Surgical Center (ASC) setting, where Glaukos estimates approximately 80% of U.S. procedures occur.
- A slight increase in proposed reimbursement for the Hospital Outpatient (HOPD) setting, representing the remaining estimated 20% of procedures.
Guidance, Outlook, and Risks
Management Commentary: Glaukos plans to actively engage with CMS during the 60-day public comment period, which closes on September 17, 2021, to advocate for appropriate payment rates. The Final Rule is expected in November 2021 for implementation on January 1, 2022.
Risks and Contingencies: The proposed rates are subject to change prior to the Final Rule. The filing notes that the iStent infinite product is not yet approved by the U.S. Food & Drug Administration, though proposed rates for its standalone insertion are included in the rule.
Investor Verification Checklist
- Verify the final CMS rule release in November 2021 to confirm if the proposed rate reductions for ASCs are adopted.
- Monitor the outcome of Glaukos' engagement during the public comment period.
- Track the FDA approval status of the iStent infinite product to assess the viability of the standalone reimbursement code (01X2T).
- Review subsequent earnings reports for the actual financial impact of the 2022 payment rate changes on revenue and margins.